Fox Chase Cancer Center News

PHILADELPHIA (December 13, 2019) – Robert Uzzo and colleagues found that type-2 papillary renal cell carcinomas were more likely to have lower pre-contrast attenuation than type-1 tumors.

PHILADELPHIA (December 11, 2019) – New research indicates that BRCA1 gene rearrangements are responsible for generating partially active proteins that drive the development of resistance to PARP inhibitors.

PHILADELPHIA (December 6, 2019) – The work of Sergei Grivennikov, PhD, is included in this year’s rankings by the Web of Science Group.

To make cancer screening more convenient for staff, Fox Chase Cancer Center kicked off its Employee Cancer Screening Initiative this October.

PHILADELPHIA (December 3, 2019) – Fox Chase Cancer Center researcher Jeffrey Peterson, PhD, has been awarded a $1.4 million grant by the U.S. Department of Defense to evaluate and exploit the mechanisms of inducing programmed cell death using polyunsaturated fatty acids in TNBC.

PHILADELPHIA (December 2, 2019) – Did you know that your chances of developing cancer may be affected by your lifestyle?  According to the American Cancer Society (ACS), an estimated 42 percent of cancer cases and 45 percent of cancer deaths in the U.S. are attributed to modifiable risk factors.

PHILADELPHIA (November 27, 2019) – Prolonged treatment with EGFR inhibitors can reduce the copies of EGFR, leading to therapy resistance, according to Johnathan R. Whetstine, PhD. Whetstine, the study’s corresponding author.

PHILADELPHIA (November 26, 2019) – Erica Golemis, PhD, professor, deputy chief science officer, leader of the Molecular Therapeutics Program, and The William Wikoff Smith Chair in Cancer Research at Fox Chase Cancer Center, has been named a 2019 Fellow of the American Association for the Advancement of Science.